Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus trough-range study in refractory partial-onset seizures associated with tuberous sclerosis complex
2011-000860-90Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of everolimus in Tuberous sclerosis complex-associated focal seizures (TSC-FS) and tuberous sclerosis complex (TSC) (3 arms), sponsored by Novartis. Primary endpoint: Response rate. Started Dec 2012; status: completed.
02
Drugs
everolimus
03
Conditions
Tuberous sclerosis complex-associated focal seizures (TSC-FS)tuberous sclerosis complex (TSC)
Beyond the preview
Go deeper on 2011-000860-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000860-90.